Cantor Fitzgerald reiterates Rocket Lab stock Overweight rating at $85 By Investing.com

Rocket Lab reported fiscal 2025 revenue of approximately $602M (a company record) and 21 successful launches in FY25 (including seven in Q4); Q4 revenue beat consensus by ~2% and Q1 revenue guidance was ~4% above consensus. Cantor Fitzgerald raised its price target to $85 from $72 and reiterated an Overweight, Needham set a $95 PT (from $110) while keeping Buy, and Craig‑Hallum raised its PT to $68 (from $55) but flagged potential downside risk to profitability. Q4 segment performance showed Space Systems revenue +29% YoY and Launch revenue +38% YoY; shares are up ~289% over the past year and trade at a P/B of 22.53, implying elevated valuation.

Analysis

Recent commercial and government wins create a two-way dynamic: steady SDA-related backlog derisks revenue realization over 6–18 months while accelerating Electron cadence is the operational lever that converts backlog into margin. The second-order beneficiaries are not just avionics and composite suppliers but ground-range operators and US launch infrastructure partners that will see lumpy demand spikes as Neutron development shifts launches from NZ to domestic pads, pressuring slot capacity and pricing for range services.

Key risks are execution and capital intensity: Neutron’s roadmap is a multi-year binary that can materially change unit economics if development slips or requires incremental capital beyond current guidance, producing steep margin compression in a single quarter. Near-term catalysts to watch are the next 90–180 day manifest confirmations, tranche milestone invoices tied to SDA funding, and any company commentary on per-launch unit costs — misses on any of these reverse sentiment quickly.

The market appears split between valuing growth optionality and discounting near-term profitability erosion; consensus underestimates the non-linear step-up in fixed-cost absorption during the Neutron development phase while simultaneously underpricing the optionality of steady defense contracts that could fund that step-up. That creates a tradable asymmetry: if cadence and tranche payments continue on schedule, upside is >2x from a base case; if development overruns emerge, downside can exceed 40% within 12 months, making hedged or time-limited exposures preferable.

Key Decisions for Investors

• Core long (directional): Accumulate RKLB on pullbacks of 15–25% over the next 3 months to build a 1–2% portfolio position; target 12–18 month hold horizon. Risk control: sell 20% of the position on a >50% rally and use a 35–40% trailing stop or size buys so a 40% drawdown equals <1% portfolio loss.
• Options-financed directional: Buy RKLB 12-month (Jan–Dec 2027) 30–35% OTM calls and finance with shorter-dated (3–6 month) OTM call sales to reduce premium. Reward: asymmetric upside to Neutron/contract wins; Risk: time decay and tech execution misses — keep net premium <30% of position notional.
• Tail-hedged long: For every $1 of stock exposure, buy 12-month puts at ~20% OTM sized to cover 25% of notional (cost funded by selling nearer-term 10–15% OTM calls). This caps catastrophic downside from a development or launch-failure event while preserving upside from SDA/backlog realization.
• Event-driven pair (6–12 months): Long RKLB / hedge ~30–40% notional by shorting a generalist space-sector ETF or less-direct play (use XSPACE-like ETF if available) to isolate company-specific execution risk. If RKLB beats cadence, expect >1.5x relative outperformance; if sector-wide derating hits, hedge limits drawdown to mid-single digits.